Kristine Kleivi Sahlberg
- Researcher; PhD
- +47 22 78 13 79
Publications 2024
The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer
Future Oncol, 20 (32), 2457-2466
DOI 10.1080/14796694.2024.2377531, PubMed 39073142
Publications 2023
Breast cancer missed at screening; hindsight or mistakes?
Eur J Radiol, 165, 110913
DOI 10.1016/j.ejrad.2023.110913, PubMed 37311339
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer
PLoS One, 18 (1), e0280507
DOI 10.1371/journal.pone.0280507, PubMed 36706086
Long-term follow-up of complex oncoplastic breast-conserving surgery, standard breast conservation and skin-sparing mastectomy in DCIS - a register-based study
Eur J Surg Oncol, 50 (2), 107938
DOI 10.1016/j.ejso.2023.107938, PubMed 38199004
Publications 2022
Subtype and cell type specific expression of lncRNAs provide insight into breast cancer
Commun Biol, 5 (1), 834
DOI 10.1038/s42003-022-03559-7, PubMed 35982125
miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy
Breast Cancer (Dove Med Press), 14, 25-39
DOI 10.2147/BCTT.S338404, PubMed 35256859
Treatment of Ductal Carcinoma in situ: A Register-Based Study of Norwegian Women Diagnosed between 1995 and 2018
Breast Care (Basel), 17 (5), 486-494
DOI 10.1159/000524564, PubMed 36684407
Oncological outcomes after simple and skin-sparing mastectomy of ductal carcinoma in situ: A register-based cohort study of 576 Norwegian women
Eur J Surg Oncol, 49 (3), 575-582
DOI 10.1016/j.ejso.2022.11.594, PubMed 36509629
NRF2 drives an oxidative stress response predictive of breast cancer
Free Radic Biol Med, 184, 170-184
DOI 10.1016/j.freeradbiomed.2022.03.029, PubMed 35381325
Publications 2021
Crosstalk between microRNA expression and DNA methylation drives the hormone-dependent phenotype of breast cancer
Genome Med, 13 (1), 72
DOI 10.1186/s13073-021-00880-4, PubMed 33926515
miRNA normalization enables joint analysis of several datasets to increase sensitivity and to reveal novel miRNAs differentially expressed in breast cancer
PLoS Comput Biol, 17 (2), e1008608
DOI 10.1371/journal.pcbi.1008608, PubMed 33566819
True and Missed Interval Cancer in Organized Mammographic Screening: A Retrospective Review Study of Diagnostic and Prior Screening Mammograms
Acad Radiol, 29 Suppl 1, S180-S191
DOI 10.1016/j.acra.2021.03.022, PubMed 33926794
MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro
Sci Rep, 11 (1), 10893
DOI 10.1038/s41598-021-90385-2, PubMed 34035375
Publications 2020
Radiological review of prior screening mammograms of screen-detected breast cancer
Eur Radiol, 31 (4), 2568-2579
DOI 10.1007/s00330-020-07130-y, PubMed 33001307
Surgical treatment of breast cancer in Norway 2003-2018
Tidsskr Nor Laegeforen, 140 (15)
DOI 10.4045/tidsskr.20.0090, PubMed 33118768
Coagulation factor V is a marker of tumor-infiltrating immune cells in breast cancer
Oncoimmunology, 9 (1), 1824644
DOI 10.1080/2162402X.2020.1824644, PubMed 33457104
Publications 2019
Interval and Consecutive Round Breast Cancer after Digital Breast Tomosynthesis and Synthetic 2D Mammography versus Standard 2D Digital Mammography in BreastScreen Norway
Radiology, 294 (2), 256-264
DOI 10.1148/radiol.2019191337, PubMed 31821118
Breast cancer quantitative proteome and proteogenomic landscape
Nat Commun, 10 (1), 1600
DOI 10.1038/s41467-019-09018-y, PubMed 30962452
miR-342-5p as a Potential Regulator of HER2 Breast Cancer Cell Growth
Microrna, 8 (2), 155-165
DOI 10.2174/2211536608666181206124922, PubMed 30520388
miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
Mol Oncol, 13 (10), 2278-2296
DOI 10.1002/1878-0261.12561, PubMed 31402562
Historical Biobanks in Breast Cancer Metabolomics- Challenges and Opportunities
Metabolites, 9 (11)
DOI 10.3390/metabo9110278, PubMed 31766128
An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment
Nat Commun, 10 (1), 5499
DOI 10.1038/s41467-019-13329-5, PubMed 31796750
Publications 2018
Subtype-specific clinical and prognostic relevance of tumor-expressed F5 and regulatory F5 variants in breast cancer: the CoCaV study
J Thromb Haemost, 16 (7), 1347-1356
DOI 10.1111/jth.14151, PubMed 29766637
Publications 2017
Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome
Breast Cancer Res, 19 (1), 44
DOI 10.1186/s13058-017-0812-y, PubMed 28356166
A novel hypoxia response element regulates oxygen-related repression of tissue factor pathway inhibitor in the breast cancer cell line MCF-7
Thromb Res, 157, 111-116
DOI 10.1016/j.thromres.2017.07.013, PubMed 28734156
DNA methylation at enhancers identifies distinct breast cancer lineages
Nat Commun, 8 (1), 1379
DOI 10.1038/s41467-017-00510-x, PubMed 29123100
Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response
Breast Cancer (Dove Med Press), 9, 185-198
DOI 10.2147/BCTT.S115600, PubMed 28356768
Publications 2016
Effect of hypoxia on tissue factor pathway inhibitor expression in breast cancer
J Thromb Haemost, 14 (2), 387-96
DOI 10.1111/jth.13206, PubMed 26598923
Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes
Cancer Metab, 4, 12
DOI 10.1186/s40170-016-0152-x, PubMed 27350877
Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors
Oncotarget, 7 (6), 6891-901
DOI 10.18632/oncotarget.6902, PubMed 26771843
Determinants of acquired activated protein C resistance and D-dimer in breast cancer
Thromb Res, 145, 78-83
DOI 10.1016/j.thromres.2016.08.003, PubMed 27505249
Publications 2015
Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer
Genome Med, 7 (1), 21
DOI 10.1186/s13073-015-0135-5, PubMed 25873999
Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF
Breast Cancer Res, 17 (1), 44
DOI 10.1186/s13058-015-0548-5, PubMed 25882602
Publications 2014
The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells - A data description
Genom Data, 2, 249-53
DOI 10.1016/j.gdata.2014.06.025, PubMed 26484103
A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients
Clin Cancer Res, 21 (5), 1207-14
DOI 10.1158/1078-0432.CCR-14-2011, PubMed 25547678
Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c
Br J Cancer, 110 (8), 2072-80
DOI 10.1038/bjc.2014.113, PubMed 24577056
Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study
BMC Cancer, 14, 845
DOI 10.1186/1471-2407-14-845, PubMed 25407022
Publications 2013
Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumors
Genome Biol, 14 (11), R126
DOI 10.1186/gb-2013-14-11-r126, PubMed 24257477
Identifying in-trans process associated genes in breast cancer by integrated analysis of copy number and expression data
PLoS One, 8 (1), e53014
DOI 10.1371/journal.pone.0053014, PubMed 23382830
High-throughput 3D screening reveals differences in drug sensitivities between culture models of JIMT1 breast cancer cells
PLoS One, 8 (10), e77232
DOI 10.1371/journal.pone.0077232, PubMed 24194875
High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth
Mol Oncol, 8 (1), 93-104
DOI 10.1016/j.molonc.2013.10.001, PubMed 24148764
Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors
Carcinogenesis, 35 (1), 76-85
DOI 10.1093/carcin/bgt333, PubMed 24104550
Publications 2012
The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells
Mol Oncol, 7 (3), 392-401
DOI 10.1016/j.molonc.2012.10.012, PubMed 23253899
Publications 2011
Identification of fusion genes in breast cancer by paired-end RNA-sequencing
Genome Biol, 12 (1), R6
DOI 10.1186/gb-2011-12-1-r6, PubMed 21247443
miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors
PLoS One, 6 (2), e16915
DOI 10.1371/journal.pone.0016915, PubMed 21364938
Gene expression profiling of human dermal fibroblasts exposed to bleomycin sulphate does not differentiate between radiation sensitive and control patients
Radiat Oncol, 6, 42
DOI 10.1186/1748-717X-6-42, PubMed 21521514
Publications 2010
Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer
Mol Oncol, 4 (4), 357-68
DOI 10.1016/j.molonc.2010.06.007, PubMed 20663721
Integrative functional genomics analysis of sustained polyploidy phenotypes in breast cancer cells identifies an oncogenic profile for GINS2
Neoplasia, 12 (11), 877-88
DOI 10.1593/neo.10548, PubMed 21082043
Publications 2009
Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines
Oncogene, 28 (44), 3926-36
DOI 10.1038/onc.2009.241, PubMed 19684618
Data integration from two microarray platforms identifies bi-allelic genetic inactivation of RIC8A in a breast cancer cell line
BMC Med Genomics, 2, 26
DOI 10.1186/1755-8794-2-26, PubMed 19432969
Publications 2007
Gene expression profiles of primary colorectal carcinomas, liver metastases, and carcinomatoses
Mol Cancer, 6, 2
DOI 10.1186/1476-4598-6-2, PubMed 17201907
Publications 2006
The order of genetic events associated with colorectal cancer progression inferred from meta-analysis of copy number changes
Genes Chromosomes Cancer, 45 (1), 31-41
DOI 10.1002/gcc.20261, PubMed 16145679
Advances in the genetics and epigenetics of gene regulation and human disease
Genome Biol, 7 (8), 325
DOI 10.1186/gb-2006-7-8-325, PubMed 16934107
ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis
Cell Oncol, 28 (5-6), 259-72
DOI 10.1155/2006/949506, PubMed 17167179
ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis
Cell. Oncol., 28 (5-6), 259-272
Publications 2005
Genome and transcriptome profiles of primary and advancedcolorectal carcinomas
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 388, 1 b. (flere pag.)
BIBSYS 06055715x, ISBN 82-8072-388-9
TP53 mutations are associated with a particular pattern of genomic imbalances in breast carcinomas
J Pathol, 207 (1), 14-9
DOI 10.1002/path.1812, PubMed 16007576
Publications 2004
Genome signatures of colon carcinoma cell lines
Cancer Genet Cytogenet, 155 (2), 119-31
DOI 10.1016/j.cancergencyto.2004.03.014, PubMed 15571797
Publications 2002
Genome profiling of breast cancer cells selected against in vitro shows copy number changes
Genes Chromosomes Cancer, 33 (3), 304-9
DOI 10.1002/gcc.10032, PubMed 11807988
Publications 2001
Genome profiles of breast- and colorectal carcinomas
K. Kleivi, Oslo, 61 s.
BIBSYS 010828753